Drospirenone / Estetrol — Competitive Intelligence Brief

Drospirenone / Estetrol (Drospirenone / Estetrol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combined oral contraceptive. Area: Contraception / Women's Health.

marketed Combined oral contraceptive Progesterone receptor, estrogen receptor Contraception / Women's Health Small molecule

Target snapshot

Drospirenone / Estetrol (Drospirenone / Estetrol) — University of Palermo. Drospirenone and estetrol work together as a hormonal contraceptive by suppressing ovulation through progestin and estrogen activity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Drospirenone / Estetrol TARGET	Drospirenone / Estetrol	University of Palermo	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor
Levonorgestrel/Ethinyl Estradiol	Levonorgestrel/Ethinyl Estradiol	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor alpha and beta
desogestrel/ethinyl estradiol	desogestrel/ethinyl estradiol	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor
YAZ®	YAZ®	Teva Pharmaceuticals USA	marketed	Oral contraceptive (combined estrogen-progestin)	Progesterone receptor, estrogen receptor, mineralocorticoid receptor
Kariva®	Kariva®	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Oral contraceptive (combined hormonal contraceptive)	Progesterone receptor, estrogen receptor
Female Contraceptive	Female Contraceptive	Italfarmaco	marketed	Hormonal contraceptive	Progesterone receptor, estrogen receptor
Continuous OC (EE/DROS)	Continuous OC (EE/DROS)	University of North Carolina, Chapel Hill	marketed	Oral contraceptive	Progesterone receptor, estrogen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combined oral contraceptive class)

1. University of Palermo · 3 drugs in this class
2. Teva Branded Pharmaceutical Products R&D, Inc. · 2 drugs in this class
3. Organon and Co · 2 drugs in this class
4. HRA Pharma · 1 drug in this class
5. Hansoh BioMedical R&D Company · 1 drug in this class
6. Helsinki University Central Hospital · 1 drug in this class
7. Hoffmann-La Roche · 1 drug in this class
8. IVI Madrid · 1 drug in this class
9. Leiden University Medical Center · 1 drug in this class
10. Massachusetts General Hospital · 1 drug in this class